Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Xencor (NASDAQ:XNCR) had its target price boosted by Cantor Fitzgerald from $43.00 to $44.00 in a research note issued on Thursday, Marketbeat Ratings reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 111.44% from the company’s current price.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. upped their target price on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Wall Street Zen downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Truist Financial reduced their price target on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Finally, Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xencor currently has an average rating of “Hold” and an average target price of $24.86.

Xencor Price Performance

Shares of XNCR stock opened at $20.81 on Thursday. The company has a market capitalization of $1.55 billion, a P/E ratio of -9.59 and a beta of 0.85. The company’s 50-day simple moving average is $15.69 and its two-hundred day simple moving average is $13.37. Xencor has a one year low of $6.92 and a one year high of $21.96.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.41) earnings per share. On average, research analysts expect that Xencor will post -3.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in shares of Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in Xencor during the second quarter worth about $79,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xencor in the fourth quarter valued at approximately $81,000. iSAM Funds UK Ltd acquired a new position in shares of Xencor in the 2nd quarter valued at $122,000. Finally, Prelude Capital Management LLC purchased a new position in shares of Xencor during the 3rd quarter worth approximately $139,000.

Key Headlines Impacting Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Quarterly results beat expectations: Xencor reported a second-quarter loss of $0.29 per share, narrower than the $0.80–$0.82 consensus estimate and better than the $0.41 loss recorded a year earlier. Revenue reached approximately $51.2 million, well above the roughly $18.9 million analyst forecast and up 17.4% year over year. Xencor Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised valuation expectations: Wedbush increased its price target from $26 to $30 and maintained an “outperform” rating. Cantor Fitzgerald also raised its target from $43 to $44 while keeping an “overweight” rating, signaling substantial potential upside based on their estimates. Analyst Price Target Updates
• Positive Sentiment: RBC Capital reaffirmed its “buy” rating for Xencor, providing additional support for the bullish analyst view following the earnings release. RBC Capital Sticks to Their Buy Rating for Xencor
• Neutral Sentiment: Brokerage consensus remains cautious: Despite several bullish individual ratings, the overall analyst consensus is “hold,” suggesting that expectations for Xencor remain mixed. Xencor Given Consensus Rating of Hold
• Negative Sentiment: Profitability remains a risk: Xencor continues to report net losses, and analysts forecast a full-year loss. The company’s negative margins mean the stock remains dependent on clinical, commercial, and partnership progress to justify its valuation.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.